Duchenne Muscular Dystrophy (DMD) Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of DMD Therapeutics | DelveInsight

DelveInsight's Duchenne Muscular Dystrophy (DMD) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline DMD therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the DMD pipeline domain.

Key takeaways from the DMD Clinical Trial Landscape Report
• DelveInsight's DMD pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Duchenne Muscular Dystrophy treatment.
• Key DMD companies such as Capricor Therapeutics, Solid Biosciences, Roche, BioMarin Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, and others
• Promising DMD pipeline therapies in various stages of development include CAP-1002, SGT-003, Satralizumab, BMN 351, DYNE 251, and others

Request a sample and discover the recent advances in DMD treatment drugs at: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Duchenne Muscular Dystrophy (DMD)?
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects males and is caused by mutations in the DMD gene, which encodes for the protein dystrophin, essential for muscle cell structure and function. The absence or malfunction of dystrophin leads to the gradual breakdown of muscle tissues over time. It is the most common hereditary neuromuscular disease and does not exhibit a predilection for any race or ethnic group. The symptoms include muscle weakness, delayed motor development, enlarged calf muscles, toe walking, and waddling gait. The treatment involves corticosteroids, physical therapy, respiratory care, cardiac management, and exon-skipping therapies. The causes are associated with mutations in the dystrophin gene. The diagnosis is based on genetic testing, creatine kinase testing, muscle biopsy, and electromyography.

Emerging DMD Drug Profiles

CAP-1002: Capricor Therapeutics
Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a population of stromal cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory, antifibrotic and regenerative actions in dystrophinopathy and heart failure. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile so that they adopt a healing, rather than a pro-inflammatory, phenotype. The therapy is currently advancing through FDA review for Duchenne Muscular Dystrophy.

SGT-003: Solid Biosciences
SGT-003 is an investigational gene therapy being developed by Solid Biosciences for Duchenne Muscular Dystrophy (DMD). The therapy is currently in Phase III clinical development and is administered intravenously. The therapy is being evaluated for its role in treating Duchenne Muscular Dystrophy and improving dystrophin expression.

Learn more about the novel and emerging DMD pipeline therapies at: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the DMD Clinical Trial Landscape
• In March 2026, Precision BioSciences, Inc. announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
• In January 2026, Atossa Therapeutics announced that the US Food and Drug Administration ("FDA") Office of Orphan Products Development ("OOPD") has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy ("DMD").
• In March 2025, Dyne Therapeutics announced new long-term clinical data from its ongoing Phase I/II DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W.
• In January 2026, Capricor Therapeutics provided a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the Company's investigational first-in-class cell therapy for the treatment of Duchenne muscular dystrophy.
• In September 2024, Capricor Therapeutics announced that it has entered into a binding term sheet with Nippon Shinyaku Co., Ltd. for the commercialization and distribution in Europe of deramiocel for the treatment of Duchenne muscular dystrophy.

Scope of the DMD Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Registered
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral
• Therapeutics Assessment By Molecule Type: Stem Cell Therapy, Gene Therapy, Monoclonal Antibody, Antisense Oligonucleotide, Cell Therapy Platform
• Key DMD Companies: Capricor Therapeutics, Solid Biosciences, Roche, BioMarin Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, and others
• Key DMD Pipeline Therapies: CAP-1002, SGT-003, Satralizumab, BMN 351, DYNE 251, and others

Dive deep into rich insights for new drugs for DMD treatment, visit https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. DMD Pipeline Report Introduction
2. DMD Pipeline Report Executive Summary
3. Duchenne Muscular Dystrophy: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. DMD Pipeline Therapeutics
6. DMD Pipeline: Late Stage Products (Registration)
7. DMD Pipeline: Late Stage Products (Phase III)
8. DMD Pipeline: Mid Stage Products (Phase II)
9. DMD Pipeline: Early Stage Products (Phase I/II)
10. DMD Pipeline Therapeutics Assessment
11. Inactive Products in the DMD Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the DMD Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the DMD pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.